Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus fulvestrant versus capecitabine for PIK3CA-mutant advanced ER-positive HER2-negative breast cancer
ACTRN12619001117101Phase 2Terminated
- Sponsor
- Breast Cancer Trials
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Alpelisib plus fulvestrant with Capecitabine (2 arms). Primary endpoint: Progression-free survival. Started Aug 2020; status: terminated.
02
Drugs
alpelisibfulvestrantcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12619001117101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001117101.